Indian stocks: Visit www.stage2stocks.com →

HeartSciences Inc.

Stage 2 · Advancing · week 8

As of Oct 22, 2026, HeartSciences is in Stage 2, the uptrend phase, now in week 8 (since Sep 1, 2026). It closed at $3.17, 39.0% below its 52-week high and above its 200-day average, which is rising.

HeartSciences Inc., a medical technology company, focuses on advancing electrocardiography (ECG) through the integration of artificial intelligence. More about the company

$3.17
-11.94% today
$15.4M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 35 in Medical Devices · #1 of 272 in Health Care

Is HSCS early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 61w
S4 14w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 61w → S1 2w → S4 11w → S1 8w → S4 10w → S1 2w → S2 9w → S3 6w → S4 2w → S3 2w → S4 13w → S1 8w → S4 14w → S1 9w → S2 7w current
Total tracked: 165 weeks across 15 stage runs.

HSCS among Medical Devices53rd of 141 by relative strength

All 141 →
Stocks in Medical Devices ranked by relative strength, with stage and one-month change
#StockStageRS1M
1TXGStage 2 · wk 4899−7.8%
2RCELStage 2 · wk 1398+40.8%
3BFLYStage 2 · wk 2698−26.0%
4HAEStage 2 · wk 1796+8.7%
5GKOSStage 2 · wk 2596+15.1%
6AXGNStage 3 · wk 295−15.3%
7NEOGStage 2 · wk 1495−11.7%
8BVSStage 2 · wk 1595+10.5%
…53HSCSStage 2 · wk 849−29.9%
vs 52W High
-39.0%
$1.67 lo$5.20 hi
39.0% below 52W high, far from high
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 8
1w13w26w
Week 8, early Stage 2
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
16.9%
200 DMA: $2.71 · rising
Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.
Rel Volume
0.52x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-29.9%
3M
+32.6%
6M
+55.4%
YTD
+1.0%
1Y
-6.2%
Scan Membership
Breakout Watch
Latest: 2025-06-09
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S2
Wk 8 · Vol 0.52x
2026-10-21S2
Wk 8 · Vol 1.26x
2026-10-20S2
Wk 7 · Vol 0.23x
2026-10-19S2
Wk 7 · Vol 0.46x
2026-10-16S2
Wk 7 · Vol 0.70x
2026-10-15S2
Wk 7 · Vol 0.39x
2026-10-14S2
Wk 7 · Vol 0.46x
2026-10-13S2
Wk 6 · Vol 0.49x
2026-10-12S2
Wk 6 · Vol 0.31x
2026-10-09S2
Wk 6 · Vol 0.59x
2026-10-08S2
Wk 6 · Vol 0.84x
2026-10-07S2
Wk 6 · Vol 0.41x
Moving averages & range
50 DMA
$3.48
200 DMA
$2.71
52W High
$5.20
52W Low
$1.67
5D Low
$3.02
Resistance levels (recent highs)
20d High
$4.73
60d High
$5.20
120d High
$5.20
250d High
$5.20
Next resistance
+49.2%
to 20d High
ROE
-1851.9%
Profit margin 0.0%
Dividend Yield
0.00%
P/B -6.1

HeartSciences: quick answers

What stage is HeartSciences in?

As of Oct 22, 2026, HeartSciences (HSCS) is in Stage 2, the uptrend phase. It entered Stage 2 on Sep 1, 2026 and is in week 8. What the four stages mean

Is HeartSciences in an uptrend?

Yes. HeartSciences is in a Stage 2 uptrend. It trades 16.9% above its 200-day average, which is rising.

How far is HeartSciences from its 52-week high?

HeartSciences closed at $3.17 on Oct 22, 2026, 39.0% below its 52-week high of $5.20. Its 52-week low is $1.67.

How has HeartSciences performed over the past year?

As of Oct 22, 2026, HeartSciences is down 6.2% over the past year and up 1.0% so far in 2026.

Which sector and industry is HeartSciences in?

HeartSciences is in the Medical Devices industry, part of the Health Care sector.

About this companyHealth Care· Medical Devices

HeartSciences Inc., a medical technology company, focuses on advancing electrocardiography (ECG) through the integration of artificial intelligence. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventional ECG information in the same test; and MyoVista Insights, a cloud-native vendor- and device-agnostic ECG management platform. The company was formerly known as Heart Test Laboratories, Inc. and changed its name to HeartSciences Inc. in October 2024. HeartSciences Inc. was incorporated in 2007 and is headquartered in Southlake, Texas.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.